Fig. 1 · Structure

Documents & Downloads

GSK1904529A

Cat. No. A10440 CAS 1089283-49-7

IGF-1R inhibitor

GSK1904529A selectively inhibits IGF-IR and IR with IC(50)s of 27 and 25 nmol/L, respectively.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In ALK-driven neuroblastoma cells, GSK1904529A inhibited IGF1R and downstream AKT phosphorylation in a model-dependent manner. NB1 cells retained substantial IGF1R phosphorylation even at 1 µM, and ALK phosphorylation showed no obvious change in this experiment. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Insulin Receptor IC50 25nM
IGF-1R IC50 27nM
B-Raf(V600E) IC50 >2μM
Syk IC50 3.2μM
VEGFR2 IC50 3.2μM
IKK3 IC50 3.2μM
AuroraB IC50 4μM
Fyn IC50 6.3μM
RSK1 IC50 6.3μM
LCK IC50 8μM
AuroraA IC50 >8μM
p38α IC50 10μM
PKCε IC50 10μM
PKCθ IC50 >10μM
ActRIIB IC50 >10μM
Akt1 IC50 >10μM
Akt2 IC50 >10μM
ALK5 IC50 >10μM
CaMKK2 IC50 >10μM
CDK2/CyclinA IC50 >10μM
EGFR IC50 >10μM
ErbB2 IC50 >10μM
JNK1 IC50 >10μM
JNK2 IC50 >10μM
JNK3 IC50 >10μM
p70S6K IC50 >10μM
PAK1 IC50 >10μM
PCTAIRE1 IC50 >10μM
PDK-1 IC50 >10μM
PI3Kα IC50 >10μM
PI3Kβ IC50 >10μM
PI3Kδ IC50 >10μM
PI3Kγ IC50 >10μM
ROCK1 IC50 >10μM
SIK2 IC50 >10μM
Src1 IC50 >10μM
YAK3 IC50 >10μM
IKK1 IC50 13μM
IKK2 IC50 13μM
JAK3 IC50 13μM
JAK2 IC50 >16μM
ZAP70 IC50 >20μM
ASK1 IC50 >25μM
ErbB4 IC50 >25μM
GSK-3β IC50 >25μM
ITK IC50 >25μM
MAPKAPK2 IC50 >25μM

47 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 20000 nM Antiproliferative activity against human A549 cells after 72 hrs by Celltiter assay [PMID: 19101143]
COLO 205 IC50 124 nM Antiproliferative activity against human COLO205 cells after 72 hrs by Celltiter assay [PMID: 19101143]
HFF IC50 > 20000 nM Antiproliferative activity against HFF cells after 72 hrs by Celltiter assay [PMID: 19101143]
LP-1 IC50 104 nM Antiproliferative activity against human LP-1 cells after 72 hrs by Celltiter assay [PMID: 19101143]
NCI-H929 IC50 81 nM Antiproliferative activity against human NCI-H929 cells after 72 hrs by Celltiter assay [PMID: 19101143]

GSK1904529A Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of GSK1904529A from 2 published references. In vitro models include CLB-BAR, CLB-GAR, CLB-GE and NB1 neuroblastoma cells; Saos-2 human osteosarcoma cells.

GSK1904529A In Vitro Studies

GSK1904529A combined with lorlatinib produced synergistic resazurin-viability responses in four neuroblastoma cell lines, while single-agent GSK1904529A had limited effects in NB1. In a separate osteosarcoma study, 250 nM GSK1904529A did not significantly induce Saos-2 apoptosis over 24–72 h despite an active methotrexate positive control. [1,2]

Context-dependent IGF1R signaling inhibition in neuroblastoma

Cell-based study · CLB-BAR and NB1 (ALK-amplified); CLB-GAR (ALK R1275Q); CLB-GE (ALK F1174V). [1]

GSK1904529A reduced pIGF1R and pAKT in CLB-BAR, CLB-GAR and CLB-GE. ERK1/2 phosphorylation decreased mainly at higher concentrations. ALK phosphorylation and total ALK showed no obvious change. NB1 retained strong pIGF1R even at 1 µM and showed little downstream response until that concentration; the explanation remains uncertain.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IGF1R, AKT, ERK1/2 and ALK phosphorylationQualitative immunoblot response pIGF1R/pAKT suppression varied by model; NB1 was comparatively unresponsive.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 10, 25, 50, 100, 250, 500 and 1000 nM
Exposure duration
2 h
Method
Single-agent treatment followed by immunoblotting.
Reported limits
The solvent for this particular experiment and the number of independent immunoblot experiments are not specified in the selected methods/caption. Uncropped blots in File S1 were not retrieved as a usable archive.
Methods and source locations

Compound reported in the paper: GSK1904529A; Compound label in the paper: GSK

Findings concern the named research compound in the reported models; salt identity, purity and Adooq lot equivalence were not established.

Results 3.3; Figure 3A–D; Methods 2.1, 2.2, 2.6

IGF1R, AKT, ERK1/2 and ALK phosphorylation: Immunoblotting; total IGF1R and ALK reprobes and tubulin loading control; 0 nM treatment comparison. — Results 3.3; Figure 3A–D; Methods 2.1, 2.2, 2.6

Lorlatinib–GSK1904529A combination response in neuroblastoma

Cell-based study · CLB-BAR, CLB-GAR, CLB-GE and NB1 neuroblastoma cells. [1]

After 72 h, combination treatment reduced resazurin viability more than the corresponding single-agent treatments. The reported combination indices were below 1 across the displayed equal-concentration pairs. GSK1904529A alone had a limited effect in CLB-BAR and NB1, particularly NB1, whereas lorlatinib alone strongly inhibited NB1. These are combination effects in cultured cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Drug interaction at 25 nM lorlatinib + 25 nM GSK1904529ACombination index (CI) CLB-BAR: 0.042; CLB-GAR: 0.095; CLB-GE: 0.316; NB1: 0.006[1]

Literature-Reported Treatment Conditions

Treatment concentration
Each drug: 10, 25, 50, 100, 250, 500 or 1000 nM in displayed equal-concentration pairs; single-agent comparators also shown.
Exposure duration
72 h
Method
Resazurin assay, normalized to DMSO-treated controls; single-agent and paired-drug conditions.
Vehicle
DMSO
Co-treatment
Lorlatinib; equal nominal concentrations of each inhibitor.
Reported limits
Figure 4 caption calls panel E IC50 values, but panel E is explicitly a concentration/CI table. No IC50 values are extracted from that panel. DMSO percentage is not specified.
Methods and source locations

Compound reported in the paper: GSK1904529A; Compound label in the paper: GSK

Findings concern the named research compound in the reported models; salt identity, purity and Adooq lot equivalence were not established.

Results 3.4; Figure 4A–E (especially table E); Methods 2.3

Drug interaction at 25 nM lorlatinib + 25 nM GSK1904529A: Resazurin viability normalized to DMSO control after 72 h; CompuSyn CI analysis. CI <1 denotes synergy. Table values have no reported ± or n attached to individual CI estimates; experiments repeated at least three times. — Figure 4E, combination 2 row; Figure 4 caption; Methods 2.3

No significant apoptosis induction in Saos-2 cells under tested conditions

Cell-based study · Saos-2 human osteosarcoma cells. [2]

At 250 nM for 24, 48 or 72 h, GSK1904529A did not significantly induce apoptosis in Saos-2 cells by three assays. Methotrexate (10 µM, 48 h) served as a positive control and increased apoptosis. The finding limits any general claim that GSK1904529A necessarily kills tumor cells by apoptosis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caspase-3 activity, histone-associated DNA fragmentation and TUNEL-positive nucleiApoptosis response No significant induction reported at 24, 48 or 72 h with 250 nM GSK1904529A.[2]

Literature-Reported Treatment Conditions

Treatment concentration
250 nM GSK1904529A; separate positive control: 10 µM methotrexate
Exposure duration
GSK1904529A: 24, 48 and 72 h; methotrexate positive control: 48 h
Method
Single-agent GSK1904529A compared with untreated Ctrl; separate positive control.
Reported limits
Solvent and vehicle-matching details are not specified. The separate figure-level n = 5 and three-repeat statements are preserved without assigning a biological-replicate hierarchy.
Methods and source locations

Compound reported in the paper: GSK1904529A; Compound label in the paper: GSK1904529A (GSK)

Findings concern the named research compound in the reported models; salt identity, purity and Adooq lot equivalence were not established.

Results “GSK1904529A fails to induce OS cell apoptosis”; Figure 3A–C; Methods apoptosis assays, chemicals and statistics

Caspase-3 activity, histone-associated DNA fragmentation and TUNEL-positive nuclei: Caspase-3 activity, histone DNA ELISA and TUNEL assays; untreated Ctrl and 10 µM methotrexate positive control. Figure 3: mean ± SD, n = 5; figure experiments repeated three times. Methods TUNEL: at least 200 cells/condition in five independent experiments; replicate hierarchy is not fully defined. — Results “GSK1904529A fails to induce OS cell apoptosis”; Figure 3A–C; Methods apoptosis assays, chemicals and statistics

GSK1904529A In Vivo Studies

In female nude mice bearing subcutaneous Saos-2 xenografts, oral GSK1904529A at 5 or 25 mg/kg once daily for 20 days suppressed tumor growth relative to vehicle during 50-day observation; the higher dose produced greater suppression. [2]

Saos-2 xenograft growth suppression in nude mice

Animal study · Female nude mice, 8–9 weeks old, bearing subcutaneous Saos-2 tumors; randomized into three groups. [2]

Oral GSK1904529A at 5 or 25 mg/kg once daily for 20 consecutive days suppressed Saos-2 xenograft growth versus vehicle during 50-day observation. The 25 mg/kg group showed greater suppression. This is a subcutaneous tumor model; no clinical efficacy or broad safety conclusion follows.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume and estimated average daily tumor growth over 50 daysTumor growth suppression Both 5 and 25 mg/kg groups: p < 0.05 versus vehicle as marked in Figure 6; no exact effect sizes extracted.[2]

Conditions shared by the study groups

Route
Oral; gavage specified in Figure 6.
Frequency
Once daily
Treatment course
20 consecutive days; observation through day 50.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlVehicle control armComparator for the tumor-volume and daily-growth analyses.[2]
GSK1904529A 5 mg/kgVehicle-treated groupTumor growth lower than vehicle; p < 0.05 marked in Figure 6.[2]
GSK1904529A 25 mg/kgVehicle-treated groupTumor growth lower than vehicle; greater suppression than the 5 mg/kg group, without a reported between-dose p value.[2]
Vehicle control
Model: Saos-2 subcutaneous xenograft in female nude mice; n = 8 per Figure 6.
Reported limits: Vehicle composition not specified; numerical volumes are not transcribed from the plotted curves.
GSK1904529A 5 mg/kg
Model: Saos-2 subcutaneous xenograft in female nude mice; n = 8 per Figure 6.
Reported limits: Vehicle composition not specified; numerical volumes are not transcribed from the plotted curves.
GSK1904529A 25 mg/kg
Model: Saos-2 subcutaneous xenograft in female nude mice; n = 8 per Figure 6.
Reported limits: Vehicle composition not specified; numerical volumes are not transcribed from the plotted curves.
Methods and source locations

Compound reported in the paper: GSK1904529A; Compound label in the paper: GSK1904529A (GSK)

Findings concern the named research compound in the reported models; salt identity, purity and Adooq lot equivalence were not established.

Results “GSK1904529A administration inhibits Saos-2 tumor growth in mice”; Figure 6A–B; Methods “Tumor xenograft assay” and “Statistical analysis”

Tumor volume and estimated average daily tumor growth over 50 days: Volume followed every 10 days through day 50; mean ± SD, n = 8 per Figure 6. Daily growth calculated as (day-50 volume minus day-0 volume)/50. One-way ANOVA with post hoc Bonferroni test stated in shared statistics. — Results “GSK1904529A administration inhibits Saos-2 tumor growth in mice”; Figure 6A–B; Methods “Tumor xenograft assay” and “Statistical analysis”

Vehicle control · Results “GSK1904529A administration inhibits Saos-2 tumor growth in mice”; Figure 6A–B; Methods “Tumor xenograft assay” and “Statistical analysis”

GSK1904529A 5 mg/kg · Results “GSK1904529A administration inhibits Saos-2 tumor growth in mice”; Figure 6A–B; Methods “Tumor xenograft assay” and “Statistical analysis”

GSK1904529A 25 mg/kg · Results “GSK1904529A administration inhibits Saos-2 tumor growth in mice”; Figure 6A–B; Methods “Tumor xenograft assay” and “Statistical analysis”

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1089283-49-7
Applications IGF-1R inhibitor
Formula C44H47F2N9O5S
Molecular Weight 852
SMILES
CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 120 mg/mL (140.85 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

GSK1904529A Research References

  1. [1] Jikui Guan, Marcus Borenäs, Junfeng Xiong, et al. IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway Cancers (2023). PMID: 37686528 DOI: 10.3390/cancers15174252 Source material
  2. [2] Hao-Dong Fei, Qi Yuan, Li Mao, et al. Assessment of GSK1904529A as a promising anti-osteosarcoma agent Oncotarget (2017). PMID: 28572530 DOI: 10.18632/oncotarget.17911 Source material

Added to your cart

View Cart Checkout
Loading...